Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same
ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS
申请人:Chow Ken
公开号:US20080194650A1
公开(公告)日:2008-08-14
The invention provides well-defined aryl fluoroethyl ureas that are useful as selective alpha
2
adrenergic agonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of alpha
2
adrenergic receptors.
[EN] NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF<br/>[FR] INHIBITEURS DE GLUCOSYLCÉRAMIDASES NON LYSOSOMALES ET LEURS UTILISATIONS
申请人:ALECTOS THERAPEUTICS INC
公开号:WO2021224864A1
公开(公告)日:2021-11-11
The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
UNSUBSTITUTED AND SUBSTITUTED 4-BENZYL-1,3-DIHYDRO-IMIDAZOLE-2-THIONES ACTING AS SPECIFIC OR SELECTIVE ALPHA2 ADRENERGIC AGONISTS AND METHODS FOR USING THE SAME
申请人:Heidelbaugh Todd M.
公开号:US20120196911A1
公开(公告)日:2012-08-02
Compounds of Formula 1
where the variables have the meaning defined in the specification are used to activate alpha
2
adrenergic receptors. The compounds of Formula 1 are incorporated in pharmaceutical compositions and are used as medicaments in mammals, including humans, for treatment of diseases and or alleviations of conditions which are responsive to treatment by agonists of alpha
2
adrenergic receptors.
Bi-functional complexes and methods for making and using such complexes
申请人:Gouliaev Alex Haahr
公开号:US11225655B2
公开(公告)日:2022-01-18
The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.